2020 annual financial data
Alnylam Pharmaceuticals 2020 Revenue growth
Direct answer
Revenue growth was 124.28%.
Operating income was -828,438,000 USD and net income was -858,281,000 USD.
Operating cash flow was -614,961,000 USD.
Get free Alnylam Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 492,853,000 USD
- Operating income
- -828,438,000 USD
- Net income
- -858,281,000 USD
- Operating cash flow
- -614,961,000 USD